Anavex Life Sciences Corp (AVXL)

[investingdog]

Key Observations – comparing Blarcamesie (AVXL), Zervimesine (CGTX) and Buntanatab (ANSV)

Efficacy Trends: All three drugs showed cognitive benefits, with blarcamesine and zervimesine focusing on slowing decline (36-39% overall, higher in subgroups), while buntanetap demonstrated actual improvement on ADAS-Cog11. Biomarker changes (e.g., Aß/tau) suggest potential disease modification across all.
Statistical Significance: Blarcamesine and buntanetap met primary endpoints with robust P values; zervimesine met safety but had mixed secondary results (significant early but not at endpoint).
Dropouts and Safety: Buntanetap had the lowest dropout rate; blarcamesine the highest (typical for longer AD trials). All were generally safe, with no major red flags beyond dose-specific issues (e.g., liver enzymes for zervimesine).
Comparison done by GROK